BioSpace News Archive

Late-breaking presentation of Phase III JAVELIN Bladder 100 data for BAVENCIO® showing overall survival benefit in first-line maintenance treatment of advanced urothelial carcinoma

Trio Pharmaceuticals, Inc. (“TRIO”), a cancer therapeutics company developing novel dual action antibody drugs, TRIObody™, and novel dual action antibody drug conjugates, TRIObody Drug Conjugate™ (TDC™) and Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development a

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI) , a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces that it has entered into a letter agreement (“Letter Agreement”) with its primary product development supplier (“Primary Supplier”) for the payment of outstanding payables. Under the

Codiak BioSciences, Inc. announced that six preclinical data presentations on its engEx™ Platform programs, of which three are oral presentations, will be presented at the 23nd Annual Meeting of the American Society of Gene and Cell Therapy, which will be held virtually on May 12-15, 2020.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2020 second quarter ended March 31, 2020, following the close of market on Thursday, May 7, 2020. The company plans to hold a conference call and live audio webcast for analys

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it will report financial results for the three months ended March 31, 2020 after the close of the U.S. financial markets on Thursday, May 7, 2020. Caladrius management will host a conference call for investor

Marrone Bio Innovations, Inc. (Nasdaq: MBII) (the “Company” or “Marrone Bio”) an international leader in sustainable bioprotection and plant health solutions, has signed a warrant exchange agreement with existing institutional investors that immediately reduces the total number of outstanding warrants by approximately 35%, from 52.6 million to 36.5 million. The warrant exchange transaction was entered into between the Company and existing inv

FDA response expected on or before June 30, 2020 Acasti also received notice of issuance of a Composition of Matter Patent in Hong Kong

XORTX Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, confirms that the Company has filed its audited financial statements and related management’s discussion and analysis for the year ended December 31, 2019.

Healthcare expert joins executive team to advance clinical informatics throughout Affinitē™, the company’s end-to-end platform for predictive care coordination, quality improvement and risk adjustment